Amgen will have the option to advance up to three large molecule programs using Entera’s oral delivery technology Entera will be eligible to receive up to $270 million in clinical and commercial milestone payments JERUSALEM , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

- - - Demonstrates positive results in three metabolic parameters in patients with hypoparathyroidism treated with Oral PTH (1-34) - - - Reports a significant decrease in 24-hour urinary calcium in hypoparathyroid patients treated with Oral PTH (1-34) - - - JERUSALEM, Israel , Nov.

JERUSALEM , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately. The appointments of Ms. Charles and Ms.

JERUSALEM , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II , MD, PhD as its new Chief Medical Officer, effective immediately. Dr. Santora has more than 30 years of experience in the biotech industry.  He has spent

Closed Initial Public Offering on July 2, 2018 Completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients Mr. Gerald Lieberman was Appointed as Chairman of the Board of Directors JERUSALEM , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd.

JERUSALEM , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as of August 6 , 2018.  “I am honored to be appointed Chairman of Entera Bio and look forward to

A second and final part of the study will evaluate selected dose regimens chosen based on part 1 JERUSALEM , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has completed the first part of the PK/PD study in hypoparathyroidism patients with its oral

JERUSALEM, June 28, 2018 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX ) (NASDAQ: ENTXW ), a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics, announced today the pricing of its initial public offering of